Nov 29 (Reuters) - Quest Pharmatech Inc QPT.V
* Quest Pharmatech says positive interim results from phase 2b clinical study of Oregovomab
* Quest Pharmatech Inc- Oregovomab in combination with chemotherapy improves clinical outcome in ovarian cancer patients Source text for Eikon: ID:nCNWpPsLqa Further company coverage: QPT.V